Optimal Duration of Anticoagulation in Deep Venous Thrombosis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 584 participants.

Also called NCT01285661

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 584 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01285661
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01285661. Allocation not applicable; no masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2015-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Optimal Duration of Anticoagulation in Deep Venous Thrombosis
Acronym
MORGAGNI
Condition
Deep Vein Thrombosis of Lower Limb
Condition
Lower Extremity Deep Venous Thrombosis Recurrent
Intervention (Drug)
Sodium warfarin
Lead sponsor
University of Padova (class: other)

Record details

Record id
cardio:ct-nct01285661
Content hash
62375d9c751425c3f862050940e08ddbb6667c32e4642abdd1daaea3a8c89303